Currently approved ICIs for HCC include monoclonal antibodies directed against cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1). Here, PDCD1 is linked to hepatocellular carcinoma.